Author: researchcanada (Research Canada)

Dr. Le Foll is a Clinician Scientist specializing in drug addiction. He is Head of the Translational Addiction Research Laboratory in the Campbell Family Mental Health Research Institute, and Medical Head of the Addiction Medicine Service at the Centre for Addiction and Mental Health. The service is providing treatment to around 4,000 new patients a year through an interdisciplinary team. He is professor at the University of Toronto in the Departments of Family and Community Medicine, Pharmacology, Psychiatry, and Institute of Medical Sciences. Dr. Le Foll received specialized training in drug addiction and behavioural and cognitive therapy at Paris University in France. He has written treatment guidelines and has been coordinator of clinical trials. In his research, he has used various approaches such as preclinical models, genetic and brain imaging.

Dr. Sellers is an internationally recognized authority on clinical psychopharmacology, pharmacogenetics, abuse liability assessment, and substance abuse, having published more than 650 papers. His focus includes accelerating early stage drug development through new methods, optimizing strategies to assess abuse potential of new and re-formulated drugs. He has worked with academic institutions, hospitals, government agencies, investors and biopharmaceutical and device companies. He was the co-founder of DecisionLine Clinical Research, a successful translational clinical research company. Dr. Sellers was Vice-President and Director at Clinical Institute of the Addiction Research Foundation, one of the world’s largest and best-known research and treatment organizations in the addiction field. He recently chaired the Scientific Advisory Panel on Opiate Analgesic Abuse for the Therapeutic Products Directorate, Health Canada.